Last Update 25 Mar 26

Fair value Decreased 46%

HCAT: New Leadership And AI Investments Will Set Up 2026 Rebound

Analysts have reduced the base case price target on Health Catalyst from $3.88 to $2.09. The revision reflects a series of lower Street targets tied to softer near term growth assumptions, a higher discount rate, and calls for more clarity around the company’s product transition and ongoing reviews.

Analyst Commentary

Recent Street research on Health Catalyst centers on lower price targets, questions around execution on its product transition, and a wait and see stance while management completes broader reviews. Q4 results and guidance commentary are key reference points for both the more optimistic and more cautious views.

Bullish Takeaways

Bullish analysts highlight elements of the story that they see as potentially supportive for growth and valuation over time, including new leadership, AI focused investments, and the market need for an applications layer in healthcare data.
Some view the current period as transitional rather than purely negative, arguing that the move from DOS to Ignite, if executed effectively, could reset the business mix and eventually support higher quality revenue.
One firm kept a Buy rating even while cutting its price target, signaling that, in its view, the current share price already reflects a meaningful amount of execution risk and review related uncertainty.
Several research notes reference Q4 results as modestly ahead of expectations or modestly better than pre release, which bullish analysts see as a sign that near term performance is not uniformly weak despite softer guidance.

Bearish Takeaways

Bearish analysts emphasize the broad reset in price targets, with multiple firms cutting levels into the US$1.75 to US$3 range and one major bank downgrade framed around there being "no easy fix" for the current setup.
Q1 revenue and EBITDA guidance below consensus and the deferral of FY26 guidance are viewed as red flags on execution, leading several firms to stay on the sidelines until there is more clarity on the outlook.
The transition from DOS to Ignite is described as a source of expected down selling and potential customer attrition in some cases, which bearish analysts see as a direct risk to revenue durability and near term growth.
Ongoing strategic and operational reviews, along with delayed long term guidance, are cited as reasons to wait for more conclusive data points before reassessing growth, profitability, or any potential rerating in the shares.

What's in the News

New CEO: Ben Albert, previously President and COO and former Upfront Healthcare CEO and Co Founder, has been appointed Chief Executive Officer and joined the Board, with former CEO Dan Burton stepping down and moving into a strategic advisor role, effective February 12, 2026 (Key Developments).
Leadership transition plan: The company accelerated its previously announced CEO succession plan, following Albert’s comprehensive review of Health Catalyst’s capabilities and focus areas after joining in 2025 (Key Developments).
Impairment charges: Health Catalyst reported goodwill and intangible asset impairment charges of $81,454,000 for the fourth quarter ended December 31, 2025, tied to fair value assessments of the Technology and Professional Services reporting units as of June 30, 2025 and December 31, 2025 (Key Developments).
2026 Q1 outlook: The company issued earnings guidance for the first quarter of 2026, expecting total revenue of $68 million to $70 million (Key Developments).
Investor activism: Whetstone Capital Advisors notified Health Catalyst that it intends to submit a shareholder proposal aimed at changes to corporate governance, including board declassification, director term limits, and giving shareholders more rights around meetings and written consents (Key Developments).

Valuation Changes

Fair Value: The base case fair value estimate moved from $3.88 to $2.09, a reduction of around 46%.
Discount Rate: The discount rate increased from 11.72% to 12.33%, a modest rise that implies a higher required return for the shares.
Revenue Growth: The revenue growth assumption shifted from a 15.09% decline to a 95.69% decline, signaling a much weaker near term revenue outlook in the model.
Net Profit Margin: The net profit margin estimate moved slightly, from 6.33% to 6.37%, indicating only a minor change in expected profitability levels.
Future P/E: The future P/E multiple moved from 20.07x to 13.26x, implying the shares are now modeled with a lower valuation multiple on future earnings.

11 views

Key Takeaways

Expansion of AI-driven solutions and proprietary data assets, along with industry trends, will drive margin growth, premium pricing, and sustained revenue gains.
Platform migration and cost restructuring set the stage for improved profitability, operating leverage, and consistent technology segment growth.
Health Catalyst faces ongoing revenue pressure from client spending cuts, strategic downsizing, and macroeconomic headwinds, with uncertain prospects for sustained growth and profitability.

Catalysts

About Health Catalyst

Provides data and analytics technology and services to healthcare organizations in the United States.What are the underlying business or industry changes driving this perspective?

The company's focus on expanding its high-margin applications portfolio, driven by ongoing client cross-sell momentum and strong adoption of modular AI-enabled solutions, is positioned to accelerate gross margin expansion and adjusted EBITDA growth as macro headwinds stabilize (positively impacting margins and earnings).
Migration of platform clients to the new Ignite infrastructure is expected to largely complete by mid-2026, at which point the current revenue headwinds from clients "pocketing" migration cost savings will subside-setting the stage for renewed and more consistent Technology segment growth (positively impacting revenue trajectory).
Secular industry drivers-including the shift to value-based care and the demand for advanced data analytics to meet regulatory and efficiency goals-are expected to support ongoing demand for Health Catalyst's core offerings, expanding its addressable market and sustaining longer-term revenue growth.
Management's proactive cost restructuring, contract repricing, and organizational streamlining are on track to deliver $40 million in annualized profitability improvements, enabling sustainable operating leverage and improvements in net margin and free cash flow-well ahead of earlier targets.
The company's substantial investment in proprietary data assets, AI/ML-driven analytics, and its ability to leverage deep integration with over 1,100 healthcare clients position it to command premium pricing, foster high retention, and benefit disproportionately as digitization and AI adoption accelerate across the healthcare sector (driving both revenue and margin expansion).

Health Catalyst Earnings and Revenue Growth

Health Catalyst Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Health Catalyst's revenue will remain fairly flat over the next 3 years.
Analysts are not forecasting that Health Catalyst will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Health Catalyst's profit margin will increase from -57.2% to the average US Healthcare Services industry of 6.4% in 3 years.
If Health Catalyst's profit margin were to converge on the industry average, you could expect earnings to reach $19.2 million (and earnings per share of $0.22) by about March 2029, up from -$178.0 million today.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 13.4x on those 2029 earnings, up from -0.5x today. This future PE is lower than the current PE for the US Healthcare Services industry at 32.9x.
Analysts expect the number of shares outstanding to grow by 5.73% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 12.33%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Significant and accelerated Medicaid and research funding cuts are causing widespread financial strain and uncertainty among Health Catalyst's core end markets-especially not-for-profit and academic medical center clients-which is leading to lower client spending, smaller extension contracts, and delayed bookings, directly impacting both near
and long-term revenue growth.
A pronounced trend of existing clients "pocketing" cost savings from Ignite platform migrations, rather than reinvesting these savings in expansion or new offerings, is compressing dollar-based net retention to the low 90s and creating persistent top-line headwinds that are expected to last at least through mid-2026.
The company's Professional Services segment faces strategic downsizing, including the exit of lower-margin or unprofitable contracts and workforce reductions impacting 9% of employees, resulting in immediate declines in Services revenue in 2025 and 2026, and introducing risk of weakened client support and scalability, negatively affecting both revenue and operating consistency.
Persistent macroeconomic pressures, such as inflation and potential expiration of premium subsidies, combined with industry conservatism and risk aversion, are causing health systems to defer or shrink technology spending, limiting the pace of Health Catalyst's pipeline conversion and new client acquisition and thus dampening revenue growth prospects for 2026 and possibly 2027.
The company's removal of ambitious 2028 revenue and EBITDA targets, stated cessation of near
to mid-term M&A activity, and reliance on maintaining profitability through restructuring rather than organic top-line growth, collectively raise concerns about Health Catalyst's ability to reignite sustainable revenue expansion-a risk that could constrain future earnings momentum and share price appreciation.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $2.09 for Health Catalyst based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $3.0, and the most bearish reporting a price target of just $1.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $302.3 million, earnings will come to $19.2 million, and it would be trading on a PE ratio of 13.4x, assuming you use a discount rate of 12.3%.
Given the current share price of $1.09, the analyst price target of $2.09 is 47.7% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Health Catalyst?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Modular AI Solutions Will Transform Value-Based Healthcare